Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29250177 | 0.89 | CA2 (0.30) | MAPT | |
| SCHEMBL29684541 | 0.88 | MAPT (0.42) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL8130138 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL8660949 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL8663867 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL16161159 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL9585705 | 0.85 | CYP1A2 (0.39) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL8679600 | 0.85 | — | — | |
| SCHEMBL3679794 | 0.85 | — | — | |
| SCHEMBL10926007 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019135-B2 | Anti-viral pyrimidine nucleoside analogues | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2006-03-28 | — | — | US | disclosed |
| EP-1280813-B1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | UNIV CARDIFF (GB) | 2003-11-12 | — | — | EP | disclosed |
| US-20030176370-A1 | Anti-viral pyrimidine nucleoside analogues | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2003-09-18 | — | — | US | disclosed |
| EP-1280813-A1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | University College Cardiff Consultants Limited (GB) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001085749-A1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176370-A1 | Anti-viral pyrimidine nucleoside analogues | CCNO, TYMP, TK1 | CYP1A2 2573/4885CYP2D6 1548/4885MAPT 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.